Fig. 2 | Nature Communications

Fig. 2

From: A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML

Fig. 2

Activity of compounds in primary AML blast samples. Primary blast samples from patients harboring a MLL rearrangement (MLLr), FLT3-internal tandem duplication positive (FLT3-ITD+), or with acute megakaryoblastic leukemia (AMKL) were plated on mesenchymal stromal cells and treated with DMSO or increasing concentrations of indicated compounds. Cell viability was determined at 96 h using Cell Titer Glo. The half maximal inhibitory concentration (IC50) was evaluated by nonlinear regression analysis using GraphPad Prism (N = 3 per concentration). Heatmap indicates IC50 concentration for each compound per patient sample

Back to article page